The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
As the first approved epidermal growth factor receptor (EGFR)-targeted therapy for nonsmall cell lung cancer (NSCLC), the clinical development of gefitinib was complex. Advances in scientific understanding of the target biology during its clinical development enabled the identification of a biomarke...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2010-09-01
|
| Series: | European Respiratory Review |
| Subjects: | |
| Online Access: | http://err.ersjournals.com/content/19/117/186.full.pdf+html |